Eslicarbazepine

Chemical formula: C₁₇H₁₆N₂O₃ Molecular mass: 254.284 g/mol

Therapeutic indications

Eslicarbazepine is indicated for:

Partial-onset seizures with or without secondary generalisation

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Eslicarbazepine is indicated as:

monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;
adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

400 mg once daily for 1-2 weeks and thereafter 800 mg once daily

10 mg/kg/day once daily and thereafter weekly or bi-weekly increments of 10-30 mg/kg/day for patients weighting <60 kg

Contraindications

Eslicarbazepine is contraindicated in the following cases:

Lactation

Second or third degree atrioventricular (AV) block

at least one of

Second degree atrioventricular block
Complete atrioventricular block

Severe hepatic impairment

Hepatic failure stage IV

Oxcarbazepine

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.